Destiny Pharma (DEST) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Mar 2023 03:29 PM
RNS
Result of General Meeting and Total Voting Rights
15 Mar 2023 04:02 PM
RNS
Result of Open Offer
06 Mar 2023 10:50 AM
RNS
Exercise of Options and Total Voting Rights
06 Mar 2023 10:31 AM
RNS
Holding(s) in Company
28 Feb 2023 03:55 PM
RNS
Posting of Circular and Notice of General Meeting
27 Feb 2023 04:30 PM
RNS
Director/PDMR Shareholding
24 Feb 2023 01:32 PM
RNS
Issue of Equity
24 Feb 2023 01:32 PM
RNS
Agreement with Sebela Pharmaceutical for NTCD-M3
24 Feb 2023 11:00 AM
RNS
Price Monitoring Extension
31 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
26 Jan 2023 10:10 AM
RNS
Exercise of Options and Total Voting Rights
25 Jan 2023 07:00 AM
RNS
US Center for Disease Control review paper
22 Dec 2022 09:05 AM
RNS
Second Price Monitoring Extn
22 Dec 2022 09:00 AM
RNS
Price Monitoring Extension
22 Dec 2022 07:00 AM
RNS
Year End Trading Update
07 Dec 2022 07:00 AM
RNS
FDA/CDC highlight need for infection preventions
07 Dec 2022 07:00 AM
RNS
XF-73 Nasal final Phase 3 development plans
02 Dec 2022 02:48 PM
RNS
Director Disclosure
23 Nov 2022 07:00 AM
RNS
Appointment of Corporate Broker
21 Nov 2022 02:19 PM
EQS
Destiny Pharma PLC 'leads the world' in new app...
18 Nov 2022 01:16 PM
RNS
Director Shareholding Amendment
15 Nov 2022 07:00 AM
RNS
XF-73 advances to clinically enabling safety study
31 Oct 2022 11:06 AM
RNS
Second Price Monitoring Extn
31 Oct 2022 11:01 AM
RNS
Price Monitoring Extension
22 Sep 2022 07:00 AM
RNS
Notice of R&D Update Meeting
08 Sep 2022 07:00 AM
RNS
Interim results for six months ended 30 June 2022
07 Sep 2022 07:03 AM
RNS
Presenting at HC Wainwright Investment Conference
07 Sep 2022 07:01 AM
RNS
Positive update from EMA on NTCD-M3 Phase 3 plans
05 Sep 2022 02:15 PM
RNS
Expiry of Share Options
22 Aug 2022 07:00 AM
RNS
Notice of Interim Results
28 Jul 2022 07:00 AM
RNS
Chair's Investor Update
26 Jul 2022 07:00 AM
RNS
Publication of new data on NTCD-M3
19 Jul 2022 07:00 AM
RNS
Positive update from US FDA on XF-73 Phase 3
12 Jul 2022 07:00 AM
RNS
Grant from the Cystic Fibrosis Foundation
07 Jul 2022 07:00 AM
RNS
Publication of XF-73 drug synergy data
05 Jul 2022 07:00 AM
RNS
New XF-73 research programme
08 Jun 2022 07:00 AM
RNS
Grant of share options
27 May 2022 11:56 AM
RNS
Result of Annual General Meeting & Strategy Update
26 May 2022 07:00 AM
RNS
Board Changes
12 May 2022 07:00 AM
RNS
Landmark NTCD-M3 data to be presented at Anaerobe
03 May 2022 07:00 AM
RNS
Destiny Pharma appoints Dr Yuri Martina as CMO
27 Apr 2022 03:34 PM
RNS
Posting of Annual Report and Notice of AGM
26 Apr 2022 03:30 PM
RNS
Director/PDMR Shareholding
12 Apr 2022 07:00 AM
RNS
Audited results for year ended 31 December 2021
04 Apr 2022 02:45 PM
RNS
Notice of Results
04 Apr 2022 02:37 PM
RNS
Notification of Major Holdings
31 Mar 2022 07:00 AM
RNS
To present data at ECCMID Congress
28 Mar 2022 11:30 AM
RNS
Result of General Meeting and Total Voting Rights
25 Mar 2022 07:00 AM
RNS
Result of Open Offer
22 Mar 2022 10:30 AM
RNS
Exercise of Options and Total Voting Rights

Destiny Pharma is a biotechnology company that develops and sells new medicines to prevent serious infections.

Destiny Pharma share price launched on AIM on August 18, 2017.

UK 100